CN106350468A - Novel lactobacillus acidophilus - Google Patents
Novel lactobacillus acidophilus Download PDFInfo
- Publication number
- CN106350468A CN106350468A CN201610809265.5A CN201610809265A CN106350468A CN 106350468 A CN106350468 A CN 106350468A CN 201610809265 A CN201610809265 A CN 201610809265A CN 106350468 A CN106350468 A CN 106350468A
- Authority
- CN
- China
- Prior art keywords
- oral liquid
- lactobacillus
- lactobacillus acidophilus
- kdb
- bacillus acidophilus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 240000001046 Lactobacillus acidophilus Species 0.000 title claims abstract description 66
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 title claims abstract description 66
- 229940039695 lactobacillus acidophilus Drugs 0.000 title abstract description 15
- 241000186660 Lactobacillus Species 0.000 claims abstract description 34
- 229940039696 lactobacillus Drugs 0.000 claims abstract description 25
- 238000000855 fermentation Methods 0.000 claims abstract description 17
- 230000004151 fermentation Effects 0.000 claims abstract description 17
- 238000002360 preparation method Methods 0.000 claims abstract description 9
- 239000007788 liquid Substances 0.000 claims description 26
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 13
- DLRVVLDZNNYCBX-UHFFFAOYSA-N Polydextrose Polymers OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(O)O1 DLRVVLDZNNYCBX-UHFFFAOYSA-N 0.000 claims description 12
- 239000001963 growth medium Substances 0.000 claims description 10
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 8
- 229930006000 Sucrose Natural products 0.000 claims description 8
- 235000013336 milk Nutrition 0.000 claims description 8
- 239000008267 milk Substances 0.000 claims description 8
- 210000004080 milk Anatomy 0.000 claims description 8
- 239000000843 powder Substances 0.000 claims description 8
- 239000002994 raw material Substances 0.000 claims description 8
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 6
- 229920001100 Polydextrose Polymers 0.000 claims description 6
- 229940109275 cyclamate Drugs 0.000 claims description 6
- HCAJEUSONLESMK-UHFFFAOYSA-N cyclohexylsulfamic acid Chemical compound OS(=O)(=O)NC1CCCCC1 HCAJEUSONLESMK-UHFFFAOYSA-N 0.000 claims description 6
- 239000008103 glucose Substances 0.000 claims description 6
- 239000001259 polydextrose Substances 0.000 claims description 6
- 229940035035 polydextrose Drugs 0.000 claims description 6
- 235000013856 polydextrose Nutrition 0.000 claims description 6
- 230000001954 sterilising effect Effects 0.000 claims description 6
- 238000003756 stirring Methods 0.000 claims description 6
- 239000000203 mixture Substances 0.000 claims description 5
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- 239000001814 pectin Substances 0.000 claims description 4
- 229920001277 pectin Polymers 0.000 claims description 4
- 235000010987 pectin Nutrition 0.000 claims description 4
- 238000004321 preservation Methods 0.000 claims description 4
- 235000013399 edible fruits Nutrition 0.000 claims description 3
- 239000012467 final product Substances 0.000 claims description 3
- 239000002609 medium Substances 0.000 claims description 3
- 229920001542 oligosaccharide Polymers 0.000 claims description 3
- 150000002482 oligosaccharides Chemical class 0.000 claims description 3
- 238000004806 packaging method and process Methods 0.000 claims description 3
- 238000012859 sterile filling Methods 0.000 claims description 3
- 239000002562 thickening agent Substances 0.000 claims description 3
- 230000001052 transient effect Effects 0.000 claims description 3
- 241001147746 Lactobacillus delbrueckii subsp. lactis Species 0.000 claims description 2
- 235000009392 Vitis Nutrition 0.000 claims description 2
- 241000219095 Vitis Species 0.000 claims description 2
- 239000007864 aqueous solution Substances 0.000 claims description 2
- 235000013325 dietary fiber Nutrition 0.000 claims description 2
- 238000012545 processing Methods 0.000 claims description 2
- 235000005911 diet Nutrition 0.000 claims 1
- 230000000378 dietary effect Effects 0.000 claims 1
- 239000000835 fiber Substances 0.000 claims 1
- 238000011081 inoculation Methods 0.000 claims 1
- 241000894006 Bacteria Species 0.000 abstract description 40
- 230000000694 effects Effects 0.000 abstract description 32
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 abstract description 25
- 230000000968 intestinal effect Effects 0.000 abstract description 13
- 235000012000 cholesterol Nutrition 0.000 abstract description 12
- 230000000844 anti-bacterial effect Effects 0.000 abstract description 9
- HHEAADYXPMHMCT-UHFFFAOYSA-N dpph Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1[N]N(C=1C=CC=CC=1)C1=CC=CC=C1 HHEAADYXPMHMCT-UHFFFAOYSA-N 0.000 abstract description 9
- 241000607142 Salmonella Species 0.000 abstract description 6
- 241000191967 Staphylococcus aureus Species 0.000 abstract description 6
- 230000003064 anti-oxidating effect Effects 0.000 abstract description 6
- 230000036541 health Effects 0.000 abstract description 6
- 238000012216 screening Methods 0.000 abstract description 6
- 241000588724 Escherichia coli Species 0.000 abstract description 4
- 241000590002 Helicobacter pylori Species 0.000 abstract description 4
- 230000009286 beneficial effect Effects 0.000 abstract description 4
- 210000004211 gastric acid Anatomy 0.000 abstract description 4
- 229940037467 helicobacter pylori Drugs 0.000 abstract description 4
- 244000005700 microbiome Species 0.000 abstract description 4
- 230000036039 immunity Effects 0.000 abstract description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 abstract description 2
- 230000005764 inhibitory process Effects 0.000 abstract 3
- 239000003833 bile salt Substances 0.000 abstract 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 46
- 239000004310 lactic acid Substances 0.000 description 23
- 235000014655 lactic acid Nutrition 0.000 description 23
- 239000006228 supernatant Substances 0.000 description 12
- 210000003743 erythrocyte Anatomy 0.000 description 11
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 10
- 241000699666 Mus <mouse, genus> Species 0.000 description 9
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 9
- -1 hydroxyl radical free radical Chemical class 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- FRXSZNDVFUDTIR-UHFFFAOYSA-N 6-methoxy-1,2,3,4-tetrahydroquinoline Chemical compound N1CCCC2=CC(OC)=CC=C21 FRXSZNDVFUDTIR-UHFFFAOYSA-N 0.000 description 8
- 230000001580 bacterial effect Effects 0.000 description 8
- 210000000941 bile Anatomy 0.000 description 8
- 239000012530 fluid Substances 0.000 description 8
- 241000699670 Mus sp. Species 0.000 description 7
- 238000003304 gavage Methods 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- 102000016938 Catalase Human genes 0.000 description 6
- 108010053835 Catalase Proteins 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 230000002401 inhibitory effect Effects 0.000 description 6
- 230000003647 oxidation Effects 0.000 description 6
- 238000007254 oxidation reaction Methods 0.000 description 6
- 210000002784 stomach Anatomy 0.000 description 6
- 230000004083 survival effect Effects 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- WSMYVTOQOOLQHP-UHFFFAOYSA-N Malondialdehyde Chemical compound O=CCC=O WSMYVTOQOOLQHP-UHFFFAOYSA-N 0.000 description 5
- 244000052616 bacterial pathogen Species 0.000 description 5
- 238000009395 breeding Methods 0.000 description 5
- 229940088598 enzyme Drugs 0.000 description 5
- 235000013305 food Nutrition 0.000 description 5
- 239000006041 probiotic Substances 0.000 description 5
- 230000000529 probiotic effect Effects 0.000 description 5
- 235000018291 probiotics Nutrition 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 4
- 102000003992 Peroxidases Human genes 0.000 description 4
- 102000019197 Superoxide Dismutase Human genes 0.000 description 4
- 108010012715 Superoxide dismutase Proteins 0.000 description 4
- 238000002835 absorbance Methods 0.000 description 4
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 4
- 235000003969 glutathione Nutrition 0.000 description 4
- 229960003180 glutathione Drugs 0.000 description 4
- 239000001301 oxygen Substances 0.000 description 4
- 229910052760 oxygen Inorganic materials 0.000 description 4
- 108040007629 peroxidase activity proteins Proteins 0.000 description 4
- 235000021108 sauerkraut Nutrition 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 241000193830 Bacillus <bacterium> Species 0.000 description 3
- 102000006587 Glutathione peroxidase Human genes 0.000 description 3
- 108700016172 Glutathione peroxidases Proteins 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000001488 breeding effect Effects 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 230000002496 gastric effect Effects 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 150000003254 radicals Chemical class 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 108020004465 16S ribosomal RNA Proteins 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 241000186016 Bifidobacterium bifidum Species 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 210000003608 fece Anatomy 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 239000008055 phosphate buffer solution Substances 0.000 description 2
- 210000002381 plasma Anatomy 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000000630 rising effect Effects 0.000 description 2
- 230000002000 scavenging effect Effects 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 1
- 241000901050 Bifidobacterium animalis subsp. lactis Species 0.000 description 1
- 241001478240 Coccus Species 0.000 description 1
- JPVYNHNXODAKFH-UHFFFAOYSA-N Cu2+ Chemical compound [Cu+2] JPVYNHNXODAKFH-UHFFFAOYSA-N 0.000 description 1
- 229930182843 D-Lactic acid Natural products 0.000 description 1
- JVTAAEKCZFNVCJ-UWTATZPHSA-N D-lactic acid Chemical compound C[C@@H](O)C(O)=O JVTAAEKCZFNVCJ-UWTATZPHSA-N 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 241000305071 Enterobacterales Species 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- 241000194036 Lactococcus Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 241000896292 Odontothrips loti Species 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 1
- 241000282894 Sus scrofa domesticus Species 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000003026 anti-oxygenic effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 230000000680 avirulence Effects 0.000 description 1
- 230000003385 bacteriostatic effect Effects 0.000 description 1
- 229940009289 bifidobacterium lactis Drugs 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000008366 buffered solution Substances 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 229940099352 cholate Drugs 0.000 description 1
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 229910001431 copper ion Inorganic materials 0.000 description 1
- 229960000935 dehydrated alcohol Drugs 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 235000013345 egg yolk Nutrition 0.000 description 1
- 210000002969 egg yolk Anatomy 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000013401 experimental design Methods 0.000 description 1
- 230000009036 growth inhibition Effects 0.000 description 1
- 230000007366 host health Effects 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- TUJKJAMUKRIRHC-UHFFFAOYSA-N hydroxyl Chemical compound [OH] TUJKJAMUKRIRHC-UHFFFAOYSA-N 0.000 description 1
- 230000007365 immunoregulation Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 230000007413 intestinal health Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- XEEYBQQBJWHFJM-UHFFFAOYSA-N iron Substances [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 1
- 238000009630 liquid culture Methods 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 230000002906 microbiologic effect Effects 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 239000006916 nutrient agar Substances 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 235000003715 nutritional status Nutrition 0.000 description 1
- 230000010355 oscillation Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 238000011056 performance test Methods 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 235000013406 prebiotics Nutrition 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 210000001187 pylorus Anatomy 0.000 description 1
- 239000010453 quartz Substances 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 238000006722 reduction reaction Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicon dioxide Inorganic materials O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 238000007711 solidification Methods 0.000 description 1
- 230000008023 solidification Effects 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000012109 statistical procedure Methods 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- CEIZFXOZIQNICU-UHFFFAOYSA-N tenuazonic acid Chemical compound CCC(C)C1NC(=O)C(C(C)=O)=C1O CEIZFXOZIQNICU-UHFFFAOYSA-N 0.000 description 1
- 230000025366 tissue development Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
- C12N1/205—Bacterial isolates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/113—Acidophilus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/225—Lactobacillus
- C12R2001/23—Lactobacillus acidophilus
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Virology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Tropical Medicine & Parasitology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
The invention relates to the technical field of microorganism screening and application, and particularly provides novel lactobacillus acidophilus with a collection number of CCTCC NO: M2016429. The novel lactobacillus acidophilus obtained by screening is high in antibacterial ability, has obvious inhibition effect on salmonella, staphylococcus aureus and helicobacter pylori and especially has strongest inhibition effect on Escherichia coli, and diameter of the inhibition zone is up to 24mm. The novel lactobacillus acidophilus can be effectively bred in gastric acid and has high tolerance to bile salt. The lactobacillus acidophilus can strongly remove cholesterol, and removal rate is up to 91.4%. The strain has high anti-oxidation ability, and removal rates of fermentation supernate of the strain to DPPH.and hydroxyl radicals are up to 92.6% and 94.1% respectively. The novel lactobacillus acidophilus can be widely applied in preparation of lactobacillus oral solutions, can obviously increase number of intestinal beneficial bacteria, improve gastrointestinal tract health and improve body immunity and has wide application prospect.
Description
Technical field
The present invention relates to microbe to screen technical field, specifically provide a kind of acidophilic lactobacilluss and its application.
Background technology
Probiotic bacteria is the quasi-microorganism being beneficial to host health, and nineteen sixty-five is suggested on science first.Intestinal
Be balance be to human nutrition and healthy vital factor, probiotic bacteria has good adjustment effect to human body intestinal canal fungus strain,
This makes the research of probiotic bacteria become a big focus of food research.In recent years, with the further investigation to probiotic bacteria, prebiotic micro-
Biological species also gets more and more, and it is broadly divided into three major types: the first kind is lactic acid bacteria, mainly includes bacillus acidophilus, excrement chain
Coccus and Bifidobacterium lactis etc.；Equations of The Second Kind is bacilluss；3rd class is yeast.
Lactic acid bacteria is avirulence, the common name of gram-positive bacterium that a class can produce lactic acid using carbohydrate,
Including at least 23 genus such as lactobacilluss, Lactococcus and bacillus bifiduss.Be considered as in selection-breeding lactobacilli strain some: (1)
The detached object of thalline should be the human or animal of health, and the bacterial strain that the mankind use is preferably derived from people.(2) it is resistant to the bile of people
Hydrochlorate and sour environment.(3) there is suitable immunoregulation effect, the untoward reaction such as inflammation will not be caused.
Lactic acid bacteria, as the important strain of microbial ecological agent, is being safeguarded humans and animals intestinal health, is being promoted internal Tiny ecosystem
Balance aspect plays an important role, and numerous studies show, lactic acid bacteria can adjust body gastrointestinal tract normal flora, keep micro- life
State balances, and improves food digestion rate and biological value, reduce serum cholesterol, control machine vivotoxin, putrefaction bacteria in suppression intestinal
Growth and breeding and the generation of spoilage product, manufacture nutrient substance, stimulate tissue development, thus to the nutritional statuses of body, physiology
Function, cell infection, drug influence, toxic reaction, immunoreation, tumor generation, aging course and unexpected emergency reaction etc.
Generation acts on.In addition, lactic acid bacteria has been widely used in the industries such as medicine, food and feedstuff as important probiotic bacteria, public
It is considered safe food-grade microorganisms.
For normal adults, microorganism in its intestinal is colonized on intestinal wall in certain population ratio, is in one
Plant in stable colony balance.But the use due to some factors such as antibiotic, radiotherapy, chemotherapy, dietary habit are bad, spiritual pressure
The reasons such as power may result in the change of normal intestinal flora type and quantity, and enteric microorganism ecosystem is destroyed, and is drawn
The pathological state rising is referred to as alteration of intestinal flora.After lactic acid bacteria enters intestinal, growth and breeding can be carried out rapidly, metabolism produces
Lactic acid, carbon dioxide make that enteral ph value is rapid to be reduced it is suppressed that the breeding of the antibacterial of pathogen and harmful health, thus rising
Effect to prevention infection, maintenance intestinal flora balance.
Lactic acid bacteria has special physiological action to human body, is requisite normal physiological flora in body, expands strain
Source, the existing excellent fermentation character of selection-breeding, there are high, excellent, the safe lactic acid bacteria culturerss of the viable count of special health care again；Should
With molecular biotechnology developing food products level lactobacilli strain and engineering bacterial strain, huge economic benefit, society will be brought for the mankind
Can benefit and ecological benefits.
Content of the invention
The present invention does not solve prior art problem, filters out a kind of acidophilic lactobacilluss from the sauerkraut juice of natural fermentation
(lactobacillus acidophilus), this bacterial strain stomach juice-resistant and bile saltss, have very strong non-oxidizability, and to big
The inhibitory action of enterobacteria is notable, has a extensive future.
One aspect of the present invention provides a kind of bacillus acidophilus kdb-03 (lactobacillus acidophilus kdb-
03), it is preserved within 29th the China typical culture collection center of Wuhan, China Wuhan University in August in 2016, preservation is compiled
Number be cctcc no:m2016429.
A kind of lactobacillus oral liquid, be by by above-mentioned bacillus acidophilus to fermenting raw materials after processing preparation.
Described raw material is the aqueous solution of milk powder, white sugar and glucose, mass volume ratio concentration g/ of wherein each raw material
Ml is respectively milk powder 3%-10%, white sugar 0.5%-8%, glucose 0.5%-6%.
Described lactobacillus oral liquid has been also added with water soluble dietary fiber, functional oligosaccharide, sweeting agent and thickening agent,
Final concentration mass volume ratio g/ml in lactobacillus oral liquid be respectively 0.5%-10%, 0.1%-2%, 0.01%-0.5%,
0.05%-0.5%.
A kind of preparation method of lactobacillus oral liquid, comprises the steps:
1) prepare fermentation medium, each component and its mass volume ratio are respectively as follows: milk powder 10%, white sugar 0.5%, Fructus Vitis viniferae
Sugar 0.5%；
2) culture medium is preheated to 50-55 DEG C, carries out homogenizing under 20-25mpa pressure condition, TRANSIENT HIGH TEMPERATURE sterilizes；
3) press 5% inoculating lactobacillus acidophilus kdb-03 of amount of fermentation, after having inoculated, continue stirring 15min；
4) control 37-40 DEG C of fermentation temperature, ferment 10 hours；
5) cold water is cooled to rapidly less than 10 DEG C, adds polydextrose, oligofructose, cyclamate and the fruit of sterilizing, mixing
Uniformly, to whole mass volume ratio (g/ml) respectively；Polydextrose 0.5%, oligofructose 2%, cyclamate 0.5%, pectin
0.5%；
6) sterile filling, packaging, warehouse-in, 2-10 DEG C of cold preservation, obtain final product lactobacillus oral liquid.
The viable count 10-30 hundred million/ml of bacillus acidophilus in described lactobacillus oral liquid.
Beneficial effect
Bacillus acidophilus' bacteriostasis that the present invention screens are very strong, and it to Salmonella, staphylococcus aureuses and is imprisoned
Door pylori all has obvious inhibitory action, and especially strong to colibacillary inhibitory action, antibacterial circle diameter reaches 24mm.Institute
State bacillus acidophilus effectively to be bred in gastric acid, and to bile saltss, there is strong tolerance.Described bacillus acidophilus kdb-
03 energy strength Cholesterol removal, clearance is up to 91.4%；This bacterial strain also has very strong oxidation resistance, its fermented supernatant fluid
92.6% and 94.1% is up to respectively to the clearance rate of dpph and hydroxyl radical free radical.Described bacillus acidophilus can be widely applied to
The preparation of lactobacillus oral liquid, can substantially increase the quantity of intestinal beneficial bacterium, improve gastrointestinal health, improve immunity of organisms,
Have a extensive future.
Specific embodiment
Embodiment 1 bacillus acidophilus' kdb-03 separation screening and identification:
1st, screening sample
The sauerkraut juice collecting natural fermentation from Shenyang Su Jiatun rural area is no dirty as separating sample, described sauerkraut juice outward appearance
Dye, good taste, fermentation time is more than 1 year, standby after filtration.
2nd, lactic acid bacteria primary dcreening operation
Take the sauerkraut juice 5ml after filtration to add 45ml sterilized water, mix, coat the mrs flat board adding 0.5% Calcium Carbonate
On, 37 DEG C of culture 48h, separation and Culture has the bacterial strain of transparent circle, obtains 42 strains of lactic acid bacteria.
3rd, antibacterial type lactic acid bacteria screening
1) lactobacillus suspension preparation: 32 strains of lactic acid bacteria that primary dcreening operation is obtained are inoculated in 100ml mrs fluid medium respectively,
37 DEG C of quiescent culture 48h；
2) pathogenic bacterium bacterium solution preparation: escherichia coli, Salmonella, staphylococcus aureuses and (four kinds of helicobacter pylori
Pathogenic bacterium are given by Shandong University), strain is inoculated in nutrient broth, 37 DEG C of shaking table cultures are overnight；
3) bacteriostatic experiment double-layer plate, Odontothrips loti: often (50 DEG C about) plus 100 μ of 5ml bactericidal nurishing agar culture medium
L pathogenic bacterium bacterium solution (bacterium amount 106The order of magnitude), mix hypsokinesis and make double-layer plate down to nutrient agar panel, in culture after solidification
Place Oxford cup on base, add the cultured lactic acid bacterial liquid of 200 μ l in Oxford cup, after bacterium solution diffusion, put into 37 DEG C of cultures
Cultivate 20h in case, observe antibacterial circle diameter.
Result shows, to escherichia coli, husky 8 Salmonellas, staphylococcus aureuses and pylorus in the lactic acid bacteria that primary dcreening operation obtains
The strain altogether of the bacterial strain all more than 15mm for the antibacterial circle diameter of pylori.Further anti-biotic resistance screening is carried out to it.Through two
Secondary delete choosing, final applicant screens from above-mentioned 8 plants of bacterium and obtains the lactic acid bacteria the strongest to colibacillary growth inhibition effect, life
Entitled kdb-03.
The inhibitory action to pathogenic bacterium for the table 1 lactic acid bacteria kdb-03
| Pathogenic bacterium | Escherichia coli | Salmonella | Staphylococcus aureuses | Helicobacter pylori |
| Antibacterial circle diameter | 24mm | 20mm | 21mm | 21mm |
As can be seen from the above table, the lactic acid bacteria kdb-03 that the present invention filters out to Salmonella, staphylococcus aureuses and
Helicobacter pylori all has obvious inhibitory action, and especially strong to colibacillary inhibitory action, antibacterial circle diameter reaches
24mm.
3rd, identification of strains
Extract the genome dna of above-mentioned lactic acid bacteria kdb-03 using test kit, expand 16s rrna sequence using pcr technology
Row.Sequencing result is carried out in genbank nucleic acid database blast and compare discovery, the 16s rrna sequence of lactic acid bacteria kdb-03
Row are higher than 99% with the sequence similarity of bacillus acidophilus (lactobacillus acidophilus).It is thus identified that it is thermophilic
Lactobacillus lactiss (lactobacillus acidophilus), are named as bacillus acidophilus kdb-03 (lactobacillus
Acidophilus kdb-03), and it is preserved within 29th the Chinese Typical Representative culture guarantor of Wuhan, China Wuhan University in August in 2016
Tibetan center, deposit number is cctcc no:m2016429.
Embodiment 2 bacillus acidophilus kdb-03 is acidproof, bile tolerance experiment
1st, stomach juice-resistant method for testing performance:
Take the bacillus acidophilus kdb-03 bacteria suspension 40ml after activation to add in 50ml centrifuge tube, be centrifuged (5000g, 5min)
Collects thalline, with adding 40ml simulated gastric fluid (to take dilute hydrochloric acid 16.4ml to add water to shake in pbs buffer solution twice backward centrifuge tube
Even be diluted to 1000ml, with concentrated hydrochloric acid or 10% naoh adjustment ph be 2.0, in 121 DEG C sterilize 30min, in sterilizing room with 1g/
100ml ratio adds pepsin), 3h are cultivated in 37 DEG C of water-baths, shake up once every 30min, live in 0h, 2h and 3h are separately sampled
Bacterium counts, and with 0h sample for comparison, calculates the survival rate of 2h and 3h sample thalline, survival rate=(viable count/0h during 2h or 3h
When viable count) × 100%.
2nd, the method for testing performance of resistance to bile saltss:
Take the bacillus acidophilus kdb-03 bacteria suspension 40ml after activation to add in 50ml centrifuge tube, be centrifuged (5000g, 5min)
Collects thalline, with adding 40ml simulated intestinal fluid (compound method: take in pbs buffer solution twice backward centrifuge tube
kh2po46.8g, plus distilled water 500ml dissolving, adjust ph value to 6.8 with the naoh solution of 0.4% (w/v), add water to 1000ml,
0.3g fowl cholate is added, after fully dissolving, in 115 DEG C of 15min that sterilize in every 100ml solution.), 2h is cultivated in 37 DEG C of water-baths, every
30min shakes up once, makees count plate in 0h, 2h and 3h are separately sampled, with 0h sample for comparison, calculates 2h and 3h sample thalline
Survival rate, survival rate=(viable count during viable count/0h during 2h or 3h) × 100%.
Meanwhile, carried out using bacillus acidophilus (lactobacillus acidophilus) cgmcc1.1854 as comparison
Above-mentioned stomach juice-resistant and resistance to bile saltss performance detection.Concrete outcome is shown in Table 2.
Table 2 bacillus acidophilus' kdb-03 stomach juice-resistant, resistance to bile saltss performance test results
Data from table 2 can be seen that compared with bacillus acidophilus cgmcc:1.1854, the acidophilus that the present invention screens
Lactobacilluss kdb-03 has very strong stomach juice-resistant, resistance to bile saltss ability, and especially its survival rate during 3h in gastric acid is up to
237.52%, not only significantly larger than control strain, and the survival rate in 2h apparently higher than bacillus acidophilus kdb-03, this says
Bright described bacillus acidophilus kdb-03 is not only able to effectively survive in gastric acid, and also achieves obvious propagation, achieves
Unexpected effect.
The removal effect to cholesterol for the embodiment 3 bacillus acidophilus kdb-03
This experiment is with reference to the method for (1998) such as brashears, and slightly improves.
It is inoculated in mrs culture medium, 37 DEG C of overnight incubation, as seed liquor after bacillus acidophilus' kdb-03 bacterial strain is activated.
Prepare the mrs culture medium containing 5% (v/v) egg yolk liquid, take wherein 2ml culture medium, 5000r/min is centrifuged 7min, takes
1ml supernatant is placed in centrifuge tube, adds 9ml dehydrated alcohol, oscillation treatment 5min, 10000r/min is centrifuged 10min, takes 2ml
Supernatant adds 2ml p-fe-s reagent, and ice bath mixes reaction 30min, surveys od550, and in calculating culture medium, cholesterol initially contains
Amount.
Then, the seed liquor of bacillus acidophilus kdb-03 is seeded in above-mentioned mrs culture medium, cultivates under the conditions of 37 DEG C
After 24h, measure the final content of cholesterol in culture medium again, calculate the clearance to cholesterol for the bacillus acidophilus kdb-03.
Simultaneously using bacillus acidophilus (lactobacillus acidophilus) cgmcc:1.1854 as control strain, using above-mentioned
Same operation, calculates the clearance to cholesterol for this bacterium.
Removal rate of cholesterol=(initial content-final content)/initial content × 100%
Result shows: the bacillus acidophilus kdb-03 that the present invention screens is high to the clearance of cholesterol in mrs culture medium
Reach 91.4%；And be equally that the control strain of bacillus acidophilus is only 19.8% to the clearance of cholesterol.Thus this is described
Bright screen bacillus acidophilus kdb-03 can strength Cholesterol removal, achieve unexpected technique effect.
Embodiment 3 bacillus acidophilus' kdb-03 antioxidation in vitro is tested
Bacillus acidophilus kdb-03 is carried out passing on after activation, mrs liquid culture is inoculated in 5% (mass ratio) inoculum concentration
Base, 37 DEG C of quiescent culture 18h, 3 000r/min, it is centrifuged 15min, collect fermentation supernatant and thalline respectively.
Prepare cell-free extract: with phosphate buffer solution (pbs) washing thalline 3 times for 7.4 for the ph value, be resuspended in
In phosphate buffer solution, adjustment bacterium number to 109cfu/ml；Then ultrasound wave ice bath crushes thalline, and 10000r/min is centrifuged
10min, supernatant is cell-free extract.
3.1dpph removes experiment
Dpph is a kind of very stable free radical centered on nitrogen, if tested material can remove it then it represents that tested material
Antioxidant effect is notable.
Dpph solution；Respectively take 1ml fermented supernatant fluid and cell-free extract, being separately added into 1ml concentration is 0.2mmol/l
Dpph, mix, under room temperature standing 30min after, 517nm at survey absorbance change.
The clearance rate (%) of dpph=[1- (a1-a2)/a3] × 100
In formula: a1 represents the original absorbance of the dpph solution of the product of sample-adding；
A2 represents absorbance when measuring wavelength for the sample itself；
A3 represents the absorbance of dpph solution after sample-adding.
Result shows: the fermented supernatant fluid of bacillus acidophilus kdb-03 and cell-free extract all can strongly remove
Dpph, its clearance rate is up to 92.6% and 81.2% respectively, thus illustrating the bacillus acidophilus kdb-03's that the present invention provides
Fermented liquid supernatant liquid and cell-free extract are respectively provided with stronger oxidation resistance, and the removing of this strain fermentation supernatant effect
Fruit will be apparently higher than cell-free extract, and the metabolite of this explanation bacillus acidophilus' kdb-03 growth period is clear to free radical
Except playing prior effect, oxidation resistance is higher.
3.2 hydroxyl radical free radicals remove experiment
In ros free radical, hydroxyl radical free radical is the most activated, exists in metal ion (as copper ion or iron ion)
Under the conditions of, superoxide anion and peroxidating Hydrogen Energy generate hydroxyl radical free radical.Hydroxyl radical free radical is a kind of very strong freedom of oxidisability
Base, can cause on biological cellular macromolecule to damage and affect the normal function of cell.Therefore, the Scavenging activity to hydroxyl radical free radical
It is a leading indicator of antioxygenic property.
Esr method measures the ability removing hydroxyl radical free radical: respectively by the fermented supernatant fluid of 50 μ l bacillus acidophilus kdb-03
Respectively it is added to after the dmpo that 50 μ l concentration are 0.3mol/l with cell-free extract, the system of reaction is transferred to the quartz of sealing
In capillary tube, then plus 50 μ l concentration be 10mol/l h2o2 start reaction.After reaction 2.5min, by er 200d src
Esr spectrometer analysis.Compare the phosphate buffered solution (ph 7.4) for 0.05mol/l.Sample to the scavenging action of oh with
Clearance rate represents.
Clearance rate=(h0—h)/h0× 100%
In formula: h and h0Represent sample respectively and compare spectroscopic signal intensity, the of the relative intensity spectroscopic signal of signal
Two peak values are representing.
Result shows: the removing to hydroxyl radical free radical of the fermented supernatant fluid of bacillus acidophilus kdb-03 and cell-free extract
Rate is up to 94.1% and 88.3% respectively, thus proving that bacillus acidophilus kdb-03 has very strong oxidation resistance further,
And the elimination effect of this strain fermentation supernatant will be apparently higher than cell-free extract.
Antioxidation zoopery in embodiment 4 body
4.1 experimental design
Internal anti-oxidation function experiment adopts high lipid oxidation Stress model.Laboratory animal is using healthy Kunming mouse 40
Only, male and female half and half, body weight 23 scholar 2g, provided by jiangsu wuxi Hui Shan south of the River laboratory animal field.Mice is raised at room temperature, freely
Search for food drinking-water, after the adaptability through 3d is raised, be randomly divided into 4 groups, every group 10, feed normal feedstuff (formula: 89.5% is common
Feedstuff, 10% Adeps Sus domestica, 0.5% cholesterol), matched group daily gavage 0.2ml normal saline, low middle high three dosage of its excess-three component
Gavage variable concentrations bacillus acidophilus kdb-03, as shown in table 3, daily 0.2ml/, continuous 4 weeks.Last is to fasting after sample
24h, gathers rapidly blood, separating red corpuscle and serum, detection erythrocyte superoxide dismutase (sod) activity, whole blood trough Guang
Sweet peptide peroxidase (gsh-px) activity, blood plasma catalase (cat) activity, Plasma MDA (mda) content, all numbers
According to all carrying out statistical procedures with statistical software spss.Test kit is purchased from Nanjing and builds up bio-engineering corporation.
The zoopery that table 3 anti-oxidation function is evaluated
4.2 interpretation of result
4.2.1 superoxide dismutase (sod)
Superoxide dismutase (sod), is to have the biological internal superoxide ion of single-minded removing, can balance the oxygen of body certainly
By base.It can remove excessive ultra-oxygen anion free radical, reduces the disease being produced by ultra-oxygen anion free radical.In the present invention
The impact to mouse red blood cell superoxide dismutase (sod) activity for the gavage bacillus acidophilus kdb-03 is shown in Table 4.
Table 4 bacillus acidophilus kdb-03 is to mouse red blood cell sod effect of vigor
| Group | Sod activity (u/mghb) |
| Matched group | 214.93±1.56 |
| Low dosage | 245.33±1.91 |
| Middle dosage | 268.79±2.16* |
| High dose | 298.38±1.36* |
* p ＜ 0.05
From table 4, it can be seen that with respect to matched group, the erythrocyte sod enzyme activity of middle dosage and high dose mice carries respectively
High by 25.1% and 38.8%, thus illustrating that the bacillus acidophilus kdb-03 of the present invention can significantly improve sod enzyme activity, have relatively
Strong oxidation resistance.
4.2.2 glutathion peroxidase (gsh-px)
Glutathion peroxidase (gsh-px) is that a kind of important catalyzing hydrogen peroxide being widely present in body divides
The enzyme of solution, is catalyzed the reduction reaction to hydrogen peroxide for the reduced glutathion, plays the effect of protection membrane structure and function.
The impact to mouse red blood cell glutathione peroxidase activity for the gavage bacillus acidophilus kdb-03 is shown in Table 5.
Table 5 bacillus acidophilus kdb-03 affects on mouse red blood cell glutathione peroxidase activity
| Group | Gsh-px (enzyme activity unit) |
| Matched group | 131.45±0.67 |
| Low dosage | 151.34±2.21 |
| Middle dosage | 174.03±3.82* |
| High dose | 189.77±2.51* |
* p ＜ 0.05
As can be seen from Table 5, middle and high dosage group mouse red blood cell glutathione peroxidase activity is up to respectively
174.03 and 189.77, improve 32.4% and 44.4% than matched group, thus confirming the bacillus acidophilus that the present invention provides
Kdb-03 can significantly improve the vigor of mouse red blood cell glutathion peroxidase.
4.2.3 catalase
Catalase generally existing in body, catalyzing hydrogen peroxide is decomposed into water and oxygen.Hydrogen peroxide is body
The harmful by-products of metabolism, are catalytically converted into the chemicals of other low toxicities through catalase, prevent body from sustaining damage.Fill
Stomach bacillus acidophilus kdb-03 is shown in Table 6 to the impact of mice catalase activity.
Table 6 gavage bacillus acidophilus kdb-03 affects on mice catalase activity
| Group | Cat activity (u/ml) |
| Matched group | 1.65±0.82 |
| Low dosage | 1.88±2.43 |
| Middle dosage | 2.74±2.89* |
| High dose | 2.94±3.15* |
* p ＜ 0.05
As can be seen from Table 6, compared with matched group, the hydrogen peroxide enzyme activity of the treatment group mice of middle and high dosage carries respectively
High by 63.9% and 75.3%, effect is significant, thus illustrate that bacillus acidophilus kdb-03 can be effectively improved the antioxidation of mice
Ability.
4.2.4 malonaldehyde
Malonaldehyde horizontal reverse has answered body inner lipid peroxidating, indirectly reflects the degree of cell injury.Gavage acidophilus
The impact to mouse red blood cell malonaldehyde level for the lactobacilluss kdb-03 is shown in Table 7.
Table 7 gavage bacillus acidophilus kdb-03 affects on mouse red blood cell malonaldehyde level
| Group | Mda content (nmol/ml) |
| Matched group | 3.44±1.87 |
| Low dosage | 3.03±1.89 |
| Middle dosage | 2.67±1.33 |
| High dose | 1.59±1.37* |
* p ＜ 0.05
As can be seen from Table 7, compared with matched group, the treatment group mda content of three dosage all substantially reduces, explanation
The bacillus acidophilus kdb-03 that the present invention provides can mitigate the damage to cell for the mice interior free yl, wherein high dose acidophilus
Lactobacilluss kdb-03 makes the content of malonaldehyde in mouse red blood cell reduce 53.8%, effect highly significant.
Embodiment 5 prepares lactobacillus oral liquid using bacillus acidophilus kdb-03
Add suitable quantity of water in preparing tank, milk powder, white sugar, glucose are added in preparing tank, stirring and dissolving, finally fixed
Hold, the mass volume ratio (g/ml) of wherein each raw material is respectively as follows: milk powder 10%, white sugar 0.5%, glucose 0.5%.By raw material
It is preheated to 50-55 DEG C, carry out homogenizing under 20-25mpa pressure condition.Using 130-135 DEG C of sterilization 4- of TRANSIENT HIGH TEMPERATURE sterilization machine
6s, controls material outlet temperature to be 30-45 DEG C.Open fermentation tank stirring, by 5% inoculating lactobacillus acidophilus kdb- of amount of fermentation
03.Continue stirring 15min after having inoculated, after fully mixing, close stirring, control 37-40 DEG C of fermentation temperature, ferment 10 hours, cold
Water is cooled to rapidly less than 10 DEG C.Add polydextrose, oligofructose, cyclamate and the pectin of sterilizing, mix homogeneously, to whole matter
Amount volume ratio (g/ml) is respectively polydextrose 0.5%, oligofructose 2%, cyclamate 0.5%, pectin 0.5%.Sterile filling,
Packaging, warehouse-in, 2-10 DEG C of cold preservation, obtain final product lactobacillus oral liquid, wherein viable count of lactobacillus is 10-30 hundred million/ml.
The effect assessment of embodiment 6 lactobacillus oral liquid
From healthy population, random choose is grown up each 20 of men and women, collects its fresh excreta and detects lactic acid bacteria therein and double
Discrimination bacillus number average out to 2.09 × 108Cfu/g and 8.04 × 109cfu/g.40 normal adults eat of the present invention daily
Lactobacillus oral liquid 50ml, detects lactic acid bacteria and bacillus bifiduss number average out to 9.55 × 10 in its fresh excreta after one week9cfu/g
With 8.91 × 1011cfu/g.In terms of result, eat this lactobacillus oral liquid and can significantly improve lactic acid bacteria and bifid in human body intestinal canal
The quantity of bacillus, is effectively improved gastrointestinal health, improves immunity of organisms, achieves unexpected technique effect.
Claims (7)
1. a kind of bacillus acidophilus are it is characterised in that the deposit number of described bacillus acidophilus is cctcc no:
m2016429.
2. a kind of lactobacillus oral liquid is it is characterised in that described lactobacillus oral liquid is by will be thermophilic described in claim 1
Lactobacillus lactiss are to processing preparation after fermenting raw materials.
3. lactobacillus oral liquid as claimed in claim 2 is it is characterised in that described raw material is milk powder, white sugar and Fructus Vitis viniferae
The aqueous solution of sugar.
4. lactobacillus oral liquid as claimed in claim 3 is it is characterised in that mass volume ratio concentration g/ml of described raw material
It is respectively milk powder 3%-10%, white sugar 0.5%-8%, glucose 0.5%-6%.
5. described lactobacillus oral liquid as arbitrary in claim 2-4 is it is characterised in that described lactobacillus oral liquid is also added with
There are water soluble dietary fiber, functional oligosaccharide, sweeting agent and thickening agent.
6. lactobacillus oral liquid as claimed in claim 5 is it is characterised in that aqueous soluble dietary in described lactobacillus oral liquid
The final concentration mass volume ratio g/ml of fiber, functional oligosaccharide, sweeting agent and thickening agent is respectively 0.5%-10%, 0.1%-
2%th, 0.01%-0.5%, 0.05%-0.5%.
7. a kind of preparation method of lactobacillus oral liquid is it is characterised in that described preparation method comprises the steps:
1) prepare fermentation medium, each component and its mass volume ratio are respectively as follows: milk powder 10%, white sugar 0.5%, glucose
0.5%；
2) culture medium is preheated to 50-55 DEG C, carries out homogenizing under 20-25mpa pressure condition, TRANSIENT HIGH TEMPERATURE sterilizes；
3) bacillus acidophilus as described in 5% inoculation claim 1 of amount of fermentation, continue stirring 15min after having inoculated；
4) control 37-40 DEG C of fermentation temperature, ferment 10 hours；
5) cold water is cooled to rapidly less than 10 DEG C, the polydextrose of addition sterilizing, oligofructose, cyclamate and fruit, mix homogeneously,
It is respectively to whole mass volume ratio (g/ml)；Polydextrose 0.5%, oligofructose 2%, cyclamate 0.5%, pectin 0.5%；
6) sterile filling, packaging, warehouse-in, 2-10 DEG C of cold preservation, obtain final product lactobacillus oral liquid.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610809265.5A CN106350468B (en) | 2016-09-08 | 2016-09-08 | A kind of acidophilic lactobacillus |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610809265.5A CN106350468B (en) | 2016-09-08 | 2016-09-08 | A kind of acidophilic lactobacillus |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN106350468A true CN106350468A (en) | 2017-01-25 |
| CN106350468B CN106350468B (en) | 2019-05-10 |
Family
ID=57859392
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610809265.5A Active CN106350468B (en) | 2016-09-08 | 2016-09-08 | A kind of acidophilic lactobacillus |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106350468B (en) |
Cited By (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106901344A (en) * | 2017-03-16 | 2017-06-30 | 北京知蜂堂健康科技股份有限公司 | A kind of composition for alleviating stomachache stomachache and its application |
| CN107495043A (en) * | 2017-09-27 | 2017-12-22 | 山东省农业科学院作物研究所 | A kind of corn full juice and milk acid bacterium drink and preparation method thereof |
| CN107593929A (en) * | 2017-10-13 | 2018-01-19 | 东北农业大学 | A kind of anti-oxidant Cheddar cheese containing Bifidobacterium and lactobacillus acidophilus and preparation method thereof |
| CN110257287A (en) * | 2019-06-21 | 2019-09-20 | 上海中优精准医疗科技股份有限公司 | A kind of lactic bacteria strain for antiallergy and skin scorching reaction |
| CN110628660A (en) * | 2018-06-22 | 2019-12-31 | 景岳生物科技(中国)有限公司 | Lactobacillus composition for inhibiting gastritis caused by gastric helicobacter pylori and application thereof |
| CN111154677A (en) * | 2020-01-13 | 2020-05-15 | 中国农业大学 | Lactobacillus acidophilus and application thereof |
| CN111304117A (en) * | 2020-01-19 | 2020-06-19 | 兰州大学 | Lactobacillus plantarum GL-5 with antioxidant activity and application thereof |
| CN114525231A (en) * | 2022-04-20 | 2022-05-24 | 微康益生菌(苏州)股份有限公司 | Lactobacillus acidophilus for resisting helicobacter pylori infection and culture method and application thereof |
| CN114736838A (en) * | 2022-06-14 | 2022-07-12 | 广东容大生物股份有限公司 | Enteromogenous probiotic strain and culture method and application thereof |
| CN114836349A (en) * | 2022-05-13 | 2022-08-02 | 江苏新申奥生物科技有限公司 | Lactobacillus acidophilus LA16 for antagonizing helicobacter pylori and application thereof |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1641014A (en) * | 2004-01-18 | 2005-07-20 | 北京三元食品股份有限公司 | Acidophilic lactobacillus and its use |
| CN102212495A (en) * | 2011-04-15 | 2011-10-12 | 北京龙科方舟生物工程技术中心 | Lactobacillus acidophilus and application thereof |
| CN103555634A (en) * | 2013-11-11 | 2014-02-05 | 山东康地恩生物科技有限公司 | Lactobacillus acidophilus and applications thereof |
| CN104928206A (en) * | 2015-04-29 | 2015-09-23 | 东北农业大学 | Lactobacillus acidophilus with high cholate hydrolase activity and application thereof |
| CN105420150A (en) * | 2015-12-08 | 2016-03-23 | 东北农业大学 | Lactobacillus acidophilus and application thereof |
| CN105586299A (en) * | 2016-03-14 | 2016-05-18 | 青岛东海药业有限公司 | Lactobacillus acidophilus preparation and application thereof |
| CN105779343A (en) * | 2016-03-28 | 2016-07-20 | 济南康多宝生物技术有限公司 | Lactobacillus plantarum capable of effectively removing cholesterol and free radicals and application thereof |
-
2016
- 2016-09-08 CN CN201610809265.5A patent/CN106350468B/en active Active
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1641014A (en) * | 2004-01-18 | 2005-07-20 | 北京三元食品股份有限公司 | Acidophilic lactobacillus and its use |
| CN102212495A (en) * | 2011-04-15 | 2011-10-12 | 北京龙科方舟生物工程技术中心 | Lactobacillus acidophilus and application thereof |
| CN103555634A (en) * | 2013-11-11 | 2014-02-05 | 山东康地恩生物科技有限公司 | Lactobacillus acidophilus and applications thereof |
| CN104928206A (en) * | 2015-04-29 | 2015-09-23 | 东北农业大学 | Lactobacillus acidophilus with high cholate hydrolase activity and application thereof |
| CN105420150A (en) * | 2015-12-08 | 2016-03-23 | 东北农业大学 | Lactobacillus acidophilus and application thereof |
| CN105586299A (en) * | 2016-03-14 | 2016-05-18 | 青岛东海药业有限公司 | Lactobacillus acidophilus preparation and application thereof |
| CN105779343A (en) * | 2016-03-28 | 2016-07-20 | 济南康多宝生物技术有限公司 | Lactobacillus plantarum capable of effectively removing cholesterol and free radicals and application thereof |
Non-Patent Citations (1)
| Title |
|---|
| 刘洋等: "4种乳酸菌体外抗氧化能力的比较研究", 《食品科学》 * |
Cited By (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106901344A (en) * | 2017-03-16 | 2017-06-30 | 北京知蜂堂健康科技股份有限公司 | A kind of composition for alleviating stomachache stomachache and its application |
| CN107495043A (en) * | 2017-09-27 | 2017-12-22 | 山东省农业科学院作物研究所 | A kind of corn full juice and milk acid bacterium drink and preparation method thereof |
| CN107495043B (en) * | 2017-09-27 | 2020-12-29 | 山东省农业科学院作物研究所 | Sweet corn whole-pulp lactobacillus beverage and preparation method thereof |
| CN107593929A (en) * | 2017-10-13 | 2018-01-19 | 东北农业大学 | A kind of anti-oxidant Cheddar cheese containing Bifidobacterium and lactobacillus acidophilus and preparation method thereof |
| CN110628660A (en) * | 2018-06-22 | 2019-12-31 | 景岳生物科技(中国)有限公司 | Lactobacillus composition for inhibiting gastritis caused by gastric helicobacter pylori and application thereof |
| CN110628660B (en) * | 2018-06-22 | 2021-06-22 | 景岳生物科技(中国)有限公司 | Lactobacillus composition for inhibiting gastritis caused by gastric helicobacter pylori and application thereof |
| CN110257287A (en) * | 2019-06-21 | 2019-09-20 | 上海中优精准医疗科技股份有限公司 | A kind of lactic bacteria strain for antiallergy and skin scorching reaction |
| CN111154677A (en) * | 2020-01-13 | 2020-05-15 | 中国农业大学 | Lactobacillus acidophilus and application thereof |
| CN111154677B (en) * | 2020-01-13 | 2022-02-01 | 中国农业大学 | Lactobacillus acidophilus and application thereof |
| CN111304117A (en) * | 2020-01-19 | 2020-06-19 | 兰州大学 | Lactobacillus plantarum GL-5 with antioxidant activity and application thereof |
| CN111304117B (en) * | 2020-01-19 | 2020-10-27 | 兰州大学 | Lactobacillus plantarum GL-5 with antioxidant activity and application thereof |
| CN114525231A (en) * | 2022-04-20 | 2022-05-24 | 微康益生菌(苏州)股份有限公司 | Lactobacillus acidophilus for resisting helicobacter pylori infection and culture method and application thereof |
| CN114525231B (en) * | 2022-04-20 | 2022-07-22 | 微康益生菌(苏州)股份有限公司 | Lactobacillus acidophilus for resisting helicobacter pylori infection and culture method and application thereof |
| CN114836349A (en) * | 2022-05-13 | 2022-08-02 | 江苏新申奥生物科技有限公司 | Lactobacillus acidophilus LA16 for antagonizing helicobacter pylori and application thereof |
| CN114836349B (en) * | 2022-05-13 | 2023-05-12 | 江苏新申奥生物科技有限公司 | Lactobacillus acidophilus LA16 for antagonizing helicobacter pylori and application thereof |
| CN114736838A (en) * | 2022-06-14 | 2022-07-12 | 广东容大生物股份有限公司 | Enteromogenous probiotic strain and culture method and application thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN106350468B (en) | 2019-05-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN106399162B (en) | A kind of novel Lactobacillus casei and its application | |
| CN106350468B (en) | A kind of acidophilic lactobacillus | |
| CN106434433B (en) | A kind of novel fermentation lactobacillus and its application in sour milk beverage | |
| CN101144065B (en) | Oxidation resistant Lactobacillus casei capable of resisting hydrogen peroxide and eliminating free radical, and use thereof | |
| CN110272842B (en) | Lactobacillus plantarum LP104 with weight-losing and lipid-lowering functions | |
| CN105779343B (en) | One plant of lactobacillus plantarum for effectively removing cholesterol and free radical and its application | |
| CN101333505B (en) | Applications of lactobacillus casei for antioxidation | |
| CN102690772B (en) | High-activity composite lactobacillus beverage and preparation method thereof | |
| CN101338283B (en) | Lactobacillus casei and applications thereof in solid-state fermentation | |
| JP2017536093A (en) | Method for producing microbial preparation and microbial preparation produced thereby | |
| CN103421715B (en) | Lactobacillus rhamnosus and application thereof | |
| CN106399163A (en) | Anti-aging probiotic preparation and preparation method thereof | |
| CN105831534B (en) | A kind of compound lactobacillus beverage and preparation method thereof | |
| CN106222158B (en) | Preparation method of lactobacillus-embedding microcapsule | |
| CN101139557A (en) | Lactobacillus casei and its application for improvement of blood lipid metabolism and immunological regulation | |
| WO2008023580A1 (en) | Animal feed additive | |
| CN106417594B (en) | A kind of compound probiotic beverage and its application | |
| CN109182162A (en) | One plant of lactobacillus plantarum and application with oxidation resistance | |
| CN103289942B (en) | Antioxidative animal bifidobacterium and applications thereof | |
| CN101333506A (en) | Lactobacillus acidophilus and antioxidation activity applications thereof | |
| CN105420150A (en) | Lactobacillus acidophilus and application thereof | |
| CN106381278B (en) | A kind of lactobacillus preparation and its application in gastric ulcer treatment | |
| CN104382160A (en) | Method for preparing lactobacillus plantarum ATCC 8014 and aloe co-fermented beverage | |
| CN104431352B (en) | A kind of preparation method and application of growth promotion symphysis unit bacterium solution | |
| CN106361778B (en) | A kind of lactobacillus preparation and its application in baby diarrhea treatment |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| CB03 | Change of inventor or designer information | ||
| CB03 | Change of inventor or designer information |
Inventor after: You Shengbo Inventor after: Hu Shunhong Inventor after: You Han Inventor after: Sun Yuyao Inventor before: You Shengbo |
|
| GR01 | Patent grant | ||
| GR01 | Patent grant |